Related Experiment Videos

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

V Bilim1, A Ougolkov, K Yuuki

  • 1Department of Urology, Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585, Japan.

British Journal of Cancer
|November 19, 2009
PubMed
Abstract

Insights

Inhibiting GSK-3beta, a protein found to accumulate in renal cell carcinoma (RCC), decreases cancer cell survival and proliferation. This suggests targeting GSK-3beta is a promising new strategy for treating RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Renal cell carcinoma (RCC) exhibits resistance to chemotherapy due to a high apoptotic threshold.
  • Glycogen synthase kinase 3 beta (GSK-3beta) is implicated in cancer cell survival via nuclear factor-kappaB (NF-kappaB) signaling.
  • Understanding GSK-3beta's role in RCC is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To determine the expression pattern of GSK-3beta in human RCC.
  • To evaluate the anti-cancer effects of inhibiting GSK-3beta in RCC.

Main Methods:

  • Immunohistochemistry and subcellular fractionation to assess GSK-3beta expression.
  • Pharmacological inhibition and RNA interference to study GSK-3beta's effects.
  • Cell proliferation and apoptosis assays (MTS, BrDU) and molecular analyses (Western blot, RT-PCR).

Main Results:

  • Aberrant nuclear accumulation of GSK-3beta was observed in 91.89% of human RCC samples.
  • GSK-3beta inhibition reduced renal cancer cell proliferation and survival.
  • Inhibition decreased NF-kappaB target genes (Bcl-2, XIAP), increasing apoptosis.
  • GSK-3beta inhibitor and Docetaxel showed synergistic effects.

Conclusions:

  • Nuclear GSK-3beta accumulation serves as a novel biomarker for human RCC.
  • GSK-3beta positively regulates RCC cell survival and proliferation.
  • Inhibiting GSK-3beta represents a promising therapeutic approach for renal cancer treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...